https:// 2020-02-27T04:21:14Z 2020-02-27T04:21:14Z kesem-health-receives-federal-government-accelerating-commercialisation-grant

Kesem Health will receive $175,000 to advance its commercialisation in the US,  enhance its ability to penetrate global markets, and raise significant growth capital. This is the third AC grant that Kesem has received, taking its funding through the AC program to a total of $1,000,000. Kesem is proud to have been selected by the office of Minister Karen Andrews, the AC committee, and the Australian Government Department of Industry, Innovation and Science through the competitive Accelerating Commercialisation grant process as part of the Entrepreneurs’ Programme. Gil Hidas, Kesem Health’s CEO, said: “The Accelerating Commercialisation program is critical to the success of Australia’s well-respected innovative eco-system. Companies like Kesem, undertaking early commercialisation, urge all levels of government to continue to advance research and development incentives of this kind”. It is important to note that Accelerating Commercialisation, coupled with the R&D Tax Incentive, are vital for Australia to build companies that will create a sustainable industry and jobs-based innovation in healthcare. Kesem Health is proud to be supported by the Australian Government through Accelerating Commercialisation, an element of the of the Entrepreneurs' Programme.  About Kesem Health and the iUFlow™ solution.Kesem Health focuses on using the iUFlow™ solution to improve, simplify, and reduce the cost of the diagnosis and management of Lower Urinary Tract diseases including Benign Prostatic Hyperplasia (BPH), Overactive Bladder (OAB), and Nocturia. Kesem is developing the world’s largest set of urinary flow data, utilising the iUFlow - a low-cost, quick, and accurate method of measuring urinary output – information that is critical for the diagnosis and management of urological conditions that affect more than 16% of the adult and juvenile population worldwide.   For more information,  visit: www.KesemHealth.com SOURCE Kesem Health Media Contact: assist@kesemHealth.com

2020-01-29T23:53:57Z darin-hammers-an-accomplished-senior-executive-with-significant-experience-in-sales-and-sales-management-in-the-medical-device-industry-and-specifically-in-urology-has-been-appointed-to-the-board-of-directors-of-kesem-health

Darin Hammers, an accomplished senior executive with significant experience in sales and sales management in the medical device industry, and specifically in urology, has been appointed to the Board of Directors of Kesem Health. As the President and Chief Executive Officer of Cogentix Medical, Mr Hammers managed a $25M fund raising in 2016.  In 2018, Mr Hammers led a $239M transaction, selling Cogentix to Laborie Medical Technologies. Other executive roles that Mr Hammers has held include VP of Sales (Urology) at Bard Medical and Director of Sales at Boston Scientific (Urology).  He is currently the CEO of Dysis Medical. Kesem Health’s initial market is the US, and the company is now in the final stages of preparation for a commercial pilot of its iUFlow™ device.  “With his more than 20 years’ experience, Mr Hammers will have a direct impact on Kesem’s success in its initial market penetration, future fund raising, and setting the strategic direction of the company”, says Gil Hidas, CEO of Kesem Health.   “We welcome Mr Hammers to our growing team and I’m looking forward working with him during 2020 and beyond”. About Kesem Health Kesem Health is a digital health company improving the convenience, accuracy, and validity of data in support of the diagnosis and management of urological conditions. Kesem has developed a patented and approved (FDA, TGA, CE Mark) wireless bladder monitoring and measurement platform that enables early, efficient diagnosis and monitoring of urological conditions. Kesem Health’s iUFlow™ is a fully automated, easy to use bladder monitoring solution, implemented on a smart phone platform.

2018-11-12T00:38:37Z kesem-health-finalist-2018-australian-technologies-competition-1

Kesem Health is honoured to be a finalist in the 2018 Australian Technologies Competition sponsored by The Department of Industry Innovation and Science, MTPConnect, METS Ignited, AustCyber, NERA and FIAL. Kesem Health is one of the top 9 incredible finalists that have been handpicked by the ATC Judges; earmarked as possessing some of Australia's greatest global potential. Kesem are the 'survivors' following 199 applications and 34 semi-finalists during 2018. The Competition serves to recruit, mentor and promote Australian's most promising technology start-ups and scaleups across a wide range of industries. Kesem Health developed and is commercialising the iUFlow™ solution to improve, simplify, and reduce the cost of the diagnosis and management of Lower Urinary Tract diseases including Benign Prostatic Hyperplasia (BPH), Overactive Bladder (OAB), and Nocturia.  

2018-10-02T01:45:17Z iuflow-finalist-in-the-best-affordable-new-technologies-in-urology-award

Kesem Health is honoured to be a finalist in the Best Affordable New Technologies in Urology competition sponsored by Prof. Daniel Yachia. This competition is part of the Symposium on Affordable New Technologies in Urology (SANTU). Prof Yachia’s aim for SANTU is to induce creative minds to create new devices and surgical techniques which will be affordable to the inhabitants of low-income countries and to help the billions of such people receive an acceptable level of treatment. The Best Affordable New Technologies in Urology-2018 is open to innovative ideas for low-cost devices and technologies that can be used in urology. “I personally think that innovations in low income countries should mainly be driven by people on the ground in the countries where they are needed. However, in addition to them, other creative minds from developed countries can also submit affordable urology related device projects aimed at people who live many miles away from them,” says Prof Yachia, who personally sponsors the competition. Kesem Health developed and is commercialising the iUFlow™ solution to improve, simplify, and reduce the cost of the diagnosis and management of Lower Urinary Tract diseases including Benign Prostatic Hyperplasia (BPH), Overactive Bladder (OAB), and Nocturia.

2018-07-23T04:48:25Z kesem-health-selected-for-andhealth-2018-australia-s-only-mid-stage-digital-health-program

Kesem Health will receive up to $60,000 worth of specialist third party services and up to $150,000 of in kind support to enhance their ability to penetrate global markets and raise significant growth capital. No transfer of equity or intellectual property rights is required to participate in the ANDHealth+ program. ANDHealth+ provides mid-stage digital health companies with support from proven experts to undertake a significant piece of work focused on securing the clinical and/or commercial evidence to enhance investment readiness and progress market entry strategy. Kesem Health was selected together with four other companies into the 2018 cohort. A highly experienced industry selection panel chose from 42 high quality submissions from across Australia. The announcement was made by The Hon. Philip Dalidakis MP, Minister for Trade and Investment, Innovation and the Digital Economy, and Small Business. "The ANDHealth+ program will support Kesem Health's continued progress in the commercialization of our novel technology. It also complements the FDA-clearance of the iUFlow™ solution and the company’s effort working towards a CE Mark for the utilization of the iUFlow™ solution in the EU market”, said Kesem Health's CEO, Gil Hidas. Bronwyn Le Grice, Managing Director and CEO of ANDHealth said: “We are excited to be working with Kesem Health over the next months to bring their evidence-based technologies closer to market and investment readiness. ANDHealth fills a crucial gap in the Australian commercialisation landscape that would otherwise leave companies like Kesem Health without expert support and guidance to progress their technology.” About Kesem Health and the iUFlow™ solution. Kesem Health focuses on using the iUFlow™ solution to improve, simplify, and reduce the cost of the diagnosis and management of Lower Urinary Tract diseases including Benign Prostatic Hyperplasia (BPH), Overactive Bladder (OAB), and Nocturia. Kesem is developing the world’s largest set of urinary flow data, utilizing the iUFlow - a low-cost, quick, and accurate method of measuring urinary output – information that is critical for the diagnosis and management of many urological conditions affecting more than 16% of the population (male, female and child), Irwin et al. About ANDHealth ANDHealth is a unique non- profit industry-led organisation focused on strengthening the Australian digital health ecosystem and de-risking innovations in digital health, with a focus on clinical evidence, commercialisation and investment readiness. ANDHealth is comprised of a consortium of industry and government partners, with foundation members drawn from industry leaders nationally and internationally including Novartis Pharmaceuticals, RMIT University, Murdoch Children’s Research Institute, Planet Innovation, Curve Tomorrow, GP2U, AusBiotech, HealthXL, and HPM Executive and matching funding provided by Federal Government Industry Growth Centre MTPConnect. For more information, visit: www.KesemHealth.com SOURCE Kesem Health    Media Contact: assist@kesemHealth.com

2015-09-16T05:41:29Z melbourne-angels-invested-in-kesem-health-iuflow

Melbourne Angels is excited to be participating in an investment round of A$355K in Kesem Health, along with the Geelong Angel Investor Network and private investors.  Kesem is developing iUFlow, an easy to use bladder monitoring home diagnostic medical device, implemented on a mobile platform.   Developed in consultation with world renowned urologists, the iUFlow will offer a digital health solution that promotes an early, efficient, accurate diagnosis and monitoring of urological conditions. In addition, the iUFlow will empower patients and provide them with real time visibility and progress of their treatment. “How quickly we were able to attract capital says a lot about our team and our new investors” says Gil Hidas, Kesem Co-founder and CEO.  “I’ve been a part of many other start-ups, so I know that being able to attract seed funding locally in just four short months  is an incredible testament to our team, product, and the quick decision making and due diligence process that the angel groups have perfected”.  “Melbourne Angels favours high value-add collaborative investments and we are enjoying our increasing syndication with our peers to fund exciting start-up companies from Australia and overseas,” said Jordan Green, Melbourne Angels Founder and President. “Gil has a combination of deep domain knowledge, superior technical expertise, and insightful vision for a rapidly evolving niche,” said Michael Vitale, Melbourne Angels Deal Lead. “He presented a well-researched idea with a truly strategic perspective on the emerging opportunities. In my conversations with key opinion leaders in the field of urology in Australia and overseas, I found that they were extremely enthusiastic about using iUFlow to improve the timeliness and accuracy of diagnosing their patients’ problems.” Geelong Angel Investor Network’s deal lead Robert Reed shared his enthusiasm for the project. “I am really looking forward to working with Gil, he has got a deep enthusiasm for iUFlow and the impact it will have for both urologists and their patients worldwide. Geelong Angel Investor Network is a new group, and iUFlow is its first investment. We look forward to assisting many more start-ups to achieve their global visions, and to collaborating with Melbourne Angels and other investor networks” said Robert. Melbourne Angels is one of the oldest and most active Angel investor groups in Australia. The group specialises in high value-add delivered to the companies in which it invests. Melbourne Angels members have some of the best track records in early-stage investment in Australia and are intimately connected to high quality opportunities and investors here and overseas. Geelong Angels is a relatively new Angel investor group, whose members want to pass on their expertise and financial investment, enabling entrepreneurial companies to make a great start on their growth journey. It is seeking additional members and is keen to also fund some quality Geelong entrepreneurial projects.  Contacts: Kesem HealthGil Hidas Gil@KesemHealth.com   Melbourne Angels Michael Vitale treasurer@melbourneangels.com +61 (0) 411 085 717 melbourneangels.com Geelong AngelsPhilippa Bakes philippa@philippabakes.com.au +61 (0) 421 551 37 geelongangels.com.au